ОНКОЛОГИЯ БЕМОРЛАРИДА ТРОМБОЦИТОПЕНИЯ ХАВФИНИ КОМПЛЕКС БАҲОЛАШ: ПРОГНОЗЛАШТИРИШДАН ПЕРСОНАЛИЗАЦИЯЛАНГАН ТЕРАПИЯГА
##article.subject##:
тромбоцитопения, онкология, тромбоцитларнинг етилмаган фракцияси, тромбопоэтин, молекуляр-генетик маркерлар##article.abstract##
Тақдим этилган мақола замонавий диагностика методологияларидан фойдаланган ҳолда онкология когортасида тромбоцитопения хавфини кўп параметрли баҳолашга қаратилган. Клиник-лаборатор ва молекуляр-генетик прогнозларни интеграциялайдиган комплекс прогнозлаштириш алгоритми ёритилган. Мақоланинг мақсади паллиатив онкологияда кўп омилли таҳлил нуқтаи назаридан тромбоцитопения хавфини баҳолашнинг диагностика ёндашувларини тизимлаштиришдан иборат. Мақолада дастлабки тромбоцитар захира миқдорини баҳолашни, генетик мойиллиликни таҳлил қилишни, тромбоцитар бўғиннинг функционал потенциалини баҳолашни ва молекуляр-генетик хавфларни стратификация қилишни ўз ичига олган концептуал ёндашув тақдим этилган.
Библиографические ссылки
Kuter DJ. Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematologica. 2022;107(6):1243-1258.
Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001;19(4):1137-1146.
Ghanima W, Cooper N, Rodeghiero F, et al. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112-1123.
Briggs C, Kunka S, Hart D, et al. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol. 2004;126(1):93-99.
Schwenkglenks M, Jackisch C, Constenla M, et al. Risk factors for chemotherapy-induced thrombocytopenia in patients with solid tumors: a pooled analysis. Support Care Cancer. 2011;19(1):33-40.
Weycker D, Hatfield M, Grossman A, et al. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer. 2019;19(1):151.
Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004;164(15):1653-1661.
Gerber DE, Seidlin M, Onstad M, et al. Incidence of and risk factors for venous thromboembolism in patients with solid tumors treated with chemotherapy. Cancer. 2013;119(14):2507-2514.
Soff GA. Angiogenesis inhibitors and thrombotic risk in cancer patients. Thromb Res. 2016;140 Suppl 1:S109-S115.
Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634.
Simanek R, Vormittag R, Hassler MR, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007;9(2):89-95.
Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22(8):1382-1388.
Low SK, Kiyotani K, Mushiroda T, et al. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet. 2009;54(10):564-571.
Gieger C, Radhakrishnan A, Cvejic A, et al. New gene functions in megakaryopoiesis and platelet formation. Nature. 2011;480(7376):201-208.
Coombs CC, Zehir A, Devlin SM, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21(3):374-382.
Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013;368(19):1771-1780.
Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362(7):600-613.
Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med. 1997;337(26):1870-1875.
Friedmann AM, Sengul H, Lehmann H, et al. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? Transfus Med Rev. 2002;16(1):34-45.
Ranucci M, Baryshnikova E, Pistuddi V, et al. The effectiveness of 10 years of interventions to control postoperative bleeding in adult cardiac surgery. Interact Cardiovasc Thorac Surg. 2019;28(2):196-202.
Görlinger K, Dirkmann D, Hanke AA, et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery. Anesthesiology. 2011;115(6):1179-1191.
Psaila B, Bussel JB, Linden MD, et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012;119(17):4066-4072.
Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145(1):24-33.
Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327-1330.
George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654-666.
Carrier M, Khorana AA, Moretto P, et al. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med. 2014;127(1):82-86.
Briggs C, Kunka S, Machin SJ. The most important new red cell parameters that analyzers can provide. Int J Lab Hematol. 2009;31(5):481-491.
Briggs C, Kunka S, Hart D, et al. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol. 2004;126(1):93-99.
Abe Y, Wada H, Tomatsu H, et al. A simple technique to determine thrombopoiesis level using immature platelet fraction (IPF). Thromb Res. 2006;118(4):463-469.
Abe Y, Nagata S, Suzuki H, et al. Immature platelet fraction as a predictor of platelet recovery after chemotherapy. Int J Lab Hematol. 2016;38(6):e108-e111.
Takami A, Shibayama M, Orito M, et al. Immature platelet fraction for prediction of platelet engraftment after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39(8):501-507.
Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115(12):3339-3347.
Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol. 1996;93(3):704-706.
Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87(10):4068-4071.
Nichol JL, Hokom MM, Hornkohl A, et al. Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest. 1995;95(6):2973-2978.
Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132.
Barraco F, Steidl U, Valent P, et al. Bone marrow cellularity and megakaryocyte morphology in primary myelofibrosis. Am J Hematol. 2015;90(11):E201-E202.
Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754-762.
Thiele J, Kvasnicka HM, Zankovich R, et al. The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) polycythemias. Haematologica. 2001;86(4):368-374.
Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thromocytopenia. J Clin Oncol. 2001;19(4):1137-1146.
Zucker ML, Murphy CA, Rachel JM, et al. Immature platelet fraction as a predictor of platelet recovery following hematopoietic progenitor cell transplantation. Lab Hematol. 2006;12(3):125-130.
Estcourt LJ, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions. Br J Haematol. 2017;176(3):365-394.
Alkhathami, A. G., Altalbawy, F. M. A., Rizaev, J. A., Jeddoa, Z. M. A., & Jabir, M. S. (2025). An overview of lncRNA GAPLINC's role in human cancer growth and metastasis. Archives of Biochemistry and Biophysics, 110506.
Irgashev, K. N., & Rizaev, J. A. (2025). Optimization of clinical outcomes in the rehabilitation of patients with non-caries dental lesions manifesting as pathological abrasion. Medical Research Journal, 1(1), 146–151.
Shakhanova, S. S., Abdurakhmonov, J. A., & Rakhimov, N. M. (2023). Targeted therapy in the palliative treatment of platinum-resistant recurrent ovarian cancer complicated by ascites. The American Journal of Medical Sciences and Pharmaceutical Research, 5(8), 1.
Rizaev, J. A., Rahimov, N. M., & Shakhanova, S. S. (2023). Prostate cancer morbidity and mortality among men in high-risk areas. Eurasian Medical Research Periodical, 18, 101–104.
